tci Medicare Compliance & Reimbursement - 2007 Issue 3
HCPCS ~ CMS Deletes Brand-New Synvisc/Hyalgan Drug Code Before It Even Takes Effect
Subscribe or sign in to view the full article.
Article Overview
This article explains a short-lived HCPCS drug code change and the replacement identifiers CMS associated with specific hyaluronan products used in intra-articular injections. It is intended for orthopedic and billing/coding staff who track HCPCS updates, payer instructions, and Medicare drug pricing file changes. The discussion also notes the relationship between the drug code and the administration procedure code, along with the possibility of insurer lag in updating claims systems.
Why This Topic Matters
These types of HCPCS updates can affect claim acceptance, payer edits, and whether practices must appeal denials when billing for injectable drugs and associated procedures.
What You Will Learn
- How CMS updates can affect HCPCS drug reporting for injectable products.
- How payer guidance and Medicare pricing files may differ during a transition period.
- Why administration coding remains relevant when reporting injectable drug services.
- What to watch for when insurers’ claim systems lag behind current HCPCS guidance.
Who Should Read This
- Orthopedic coders
- Medical billers
- Practice managers
- Revenue cycle staff
- Physician offices
- Outpatient orthopedic practices
Codes Discussed
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com